N 2749
Latest Information Update: 11 Dec 2007
Price :
$50 *
At a glance
- Originator Nisshin Pharma
- Class Osteoporosis therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 12 Dec 2003 No development reported - Preclinical for Postmenopausal osteoporosis in Japan (unspecified route)
- 11 Sep 2000 Preclinical development for Postmenopausal osteoporosis in Japan (Unknown route)
- 25 Mar 1999 No-Development-Reported for Postmenopausal osteoporosis in Japan (Unknown route)